CONMED Corporation reported strong growth in both Orthopedics and General Surgery for the second quarter of 2023. The company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.230 billion and $1.260 billion. The Company now expects full-year 2023 adjusted diluted net earnings per share in the range of $3.40 to $3.55.
Excellent growth in both Orthopedics and General Surgery.
Built on the momentum generated during the first three months of the year.
Confident in ability to grow above market.
Continue to deliver clinical innovation to customers.
CONMED is raising its revenue guidance for the full year 2023 and now expects revenue between $1.230 billion and $1.260 billion, compared to its prior guidance of between $1.205 billion and $1.250 billion. The Company now expects full-year 2023 adjusted diluted net earnings per share in the range of $3.40 to $3.55, compared to its prior range of $3.30 to $3.50.